Intercept Pharmaceuticals Inc (NASDAQ:ICPT) insider David Shapiro sold 2,000 shares of the company’s stock in a transaction on Monday, April 15th. The stock was sold at an average price of $95.00, for a total transaction of $190,000.00. Following the transaction, the insider now owns 41,499 shares of the company’s stock, valued at $3,942,405. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.

David Shapiro also recently made the following trade(s):

  • On Wednesday, April 3rd, David Shapiro sold 562 shares of Intercept Pharmaceuticals stock. The stock was sold at an average price of $115.01, for a total transaction of $64,635.62.
  • On Friday, March 1st, David Shapiro sold 2,000 shares of Intercept Pharmaceuticals stock. The stock was sold at an average price of $103.16, for a total transaction of $206,320.00.
  • On Friday, February 15th, David Shapiro sold 2,000 shares of Intercept Pharmaceuticals stock. The stock was sold at an average price of $111.51, for a total transaction of $223,020.00.

NASDAQ:ICPT traded down $0.55 during mid-day trading on Tuesday, hitting $91.70. The stock had a trading volume of 1,207,904 shares, compared to its average volume of 1,020,604. The stock has a market cap of $2.74 billion, a price-to-earnings ratio of -8.44 and a beta of 1.63. Intercept Pharmaceuticals Inc has a twelve month low of $64.50 and a twelve month high of $133.74. The company has a quick ratio of 4.22, a current ratio of 4.22 and a debt-to-equity ratio of 19.41.

Intercept Pharmaceuticals (NASDAQ:ICPT) last issued its earnings results on Thursday, February 28th. The biopharmaceutical company reported ($2.97) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($2.42) by ($0.55). The firm had revenue of $53.30 million during the quarter, compared to analyst estimates of $52.53 million. Intercept Pharmaceuticals had a negative net margin of 172.39% and a negative return on equity of 592.58%. The firm’s revenue was up 41.4% compared to the same quarter last year. During the same period last year, the business earned ($4.43) EPS. On average, equities analysts anticipate that Intercept Pharmaceuticals Inc will post -9.1 EPS for the current year.

A number of equities analysts have weighed in on ICPT shares. BidaskClub upgraded shares of Intercept Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Tuesday, December 18th. Zacks Investment Research upgraded shares of Intercept Pharmaceuticals from a “hold” rating to a “buy” rating and set a $97.00 price objective for the company in a research report on Monday, December 31st. Laidlaw raised shares of Intercept Pharmaceuticals from a “hold” rating to a “buy” rating and upped their target price for the stock from $99.00 to $130.00 in a report on Monday, January 14th. Jefferies Financial Group upped their target price on shares of Intercept Pharmaceuticals to $150.00 and gave the stock a “buy” rating in a report on Monday, January 28th. Finally, Needham & Company LLC raised shares of Intercept Pharmaceuticals from a “hold” rating to a “buy” rating and set a $150.00 price objective for the company in a report on Thursday, January 24th. Two research analysts have rated the stock with a sell rating, six have assigned a hold rating and sixteen have assigned a buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus target price of $144.05.

Large investors have recently modified their holdings of the stock. Prudential Financial Inc. purchased a new position in Intercept Pharmaceuticals in the third quarter valued at approximately $293,000. Bank of New York Mellon Corp increased its stake in Intercept Pharmaceuticals by 3.7% in the third quarter. Bank of New York Mellon Corp now owns 93,227 shares of the biopharmaceutical company’s stock valued at $11,780,000 after purchasing an additional 3,342 shares during the last quarter. Hsbc Holdings PLC purchased a new position in Intercept Pharmaceuticals in the third quarter valued at approximately $748,000. Pacer Advisors Inc. purchased a new position in Intercept Pharmaceuticals in the third quarter valued at approximately $417,000. Finally, MetLife Investment Advisors LLC increased its stake in Intercept Pharmaceuticals by 46.0% in the third quarter. MetLife Investment Advisors LLC now owns 14,825 shares of the biopharmaceutical company’s stock valued at $1,873,000 after purchasing an additional 4,672 shares during the last quarter. 70.24% of the stock is currently owned by hedge funds and other institutional investors.

WARNING: “Insider Selling: Intercept Pharmaceuticals Inc (ICPT) Insider Sells 2,000 Shares of Stock” was published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this article on another website, it was illegally stolen and reposted in violation of US & international copyright law. The legal version of this article can be viewed at https://www.thecerbatgem.com/2019/04/16/insider-selling-intercept-pharmaceuticals-inc-icpt-insider-sells-2000-shares-of-stock.html.

Intercept Pharmaceuticals Company Profile

Intercept Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases. It markets Ocaliva, an farnesoid X receptor agonist approved in the United States, the European Union, and other jurisdictions for the treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid in adults.

See Also: What is the NASDAQ Stock Market?

Insider Buying and Selling by Quarter for Intercept Pharmaceuticals (NASDAQ:ICPT)

Receive News & Ratings for Intercept Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intercept Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.